Search results for "DASES"

showing 10 items of 485 documents

Clinical and genetic characteristics of 21 Spanish patients with biallelic pathogenic SPG7 mutations.

2021

Spastic paraplegia type 7 (SPG7) is one of the most common hereditary spastic paraplegias. SPG7 mutations most often lead to spastic paraparesis (HSP) and/or hereditary cerebellar ataxia (HCA), frequently with mixed phenotypes. We sought to clinically and genetically characterize a Spanish cohort of SPG7 patients. Patients were recruited from our HCA and HSP cohorts. We identified twenty-one patients with biallelic pathogenic SPG7 mutations. Mean age at onset was 37.4 years (SD ± 14.3). The most frequent phenotype was spastic ataxia (57%), followed by pure spastic paraplegia (19%) and complex phenotypes (19%). Isolated patients presented with focal or multifocal dystonia, subclinical myopat…

medicine.medical_specialtyNeurogeneticsCompound heterozygosityGastroenterologyInternal medicinemedicineSpasticHumansMyopathySubclinical infectionDystoniaCerebellar ataxiabusiness.industrySpastic Paraplegia HereditaryMetalloendopeptidasesmedicine.diseasenervous system diseasesOptic AtrophyPhenotypeNeurologyMutationATPases Associated with Diverse Cellular ActivitiesNeurology (clinical)medicine.symptombusinessSpastic paraplegia type 7Journal of the neurological sciences
researchProduct

Expression pattern of matrix metalloproteinases-2 and -9 and their tissue inhibitors in patients with chronic inflammatory demyelinating polyneuropat…

2021

Background: Matrix metalloproteinases (MMPs) are a heterogeneous family of endopeptidases that play a role in many physiological functions, including the immune response. An imbalance between the activity of MMPs and their physiological tissue inhibitors (TIMPs) has been proposed in the pathophysiology of different autoimmune disorders. We aimed to assess the plasmatic levels of MMP-2, MMP-9, and their inhibitors TIMP-1 and -2 in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Subjects and methods: Twenty patients with CIDP and 20 age- and sex-matched healthy controls were enrolled. Plasma concentrations of MMP-2, MMP-9, TIMP-1, and TIMP-2 were determined by the enzy…

medicine.medical_specialtyNeurologyChronic inflammatory demyelinating polyneuropathyCIDPDermatologyMatrix metalloproteinaseGastroenterologyTissue inhibitor of matrix metalloproteinase03 medical and health sciences0302 clinical medicineImmune systemExpression patternDownregulation and upregulationInternal medicineEndopeptidasesmedicineTIMPHumansIn patient030212 general & internal medicineMMPbusiness.industryGeneral Medicinemedicine.diseaseMatrix MetalloproteinasesPathophysiologyMatrix metalloproteinasePsychiatry and Mental healthMatrix Metalloproteinase 9Polyradiculoneuropathy Chronic Inflammatory DemyelinatingMatrix Metalloproteinase 2Settore MED/26 - NeurologiaNeurology (clinical)business030217 neurology & neurosurgeryNeurological Sciences
researchProduct

NADPH Oxidase Accounts for Enhanced Superoxide Production and Impaired Endothelium-Dependent Smooth Muscle Relaxation in BKβ1 −/− Mice

2006

Objective— Nitric oxide (NO)-induced vasorelaxation involves activation of large conductance Ca 2+ -activated K + channels (BK). A regulatory BKβ1 subunit confers Ca 2+ , voltage, and NO/cGMP sensitivity to the BK channel. We investigated whether endothelial function and NO/cGMP signaling is affected by a deletion of the β1-subunit. Methods and Results— Vascular superoxide in BKβ1 −/− was measured using the fluorescent dye hydroethidine and lucigenin-enhanced chemiluminescence. Vascular NO formation was analyzed using electron paramagnetic resonance (EPR), expression of NADPH oxidase subunits, the endothelial NO synthase (eNOS), the soluble guanylyl cyclase (sGC), as well as the activity a…

medicine.medical_specialtyNitric Oxide Synthase Type IIIEndotheliumAorta ThoracicNitric OxideMuscle Smooth VascularNitric oxideMicechemistry.chemical_compoundSuperoxidesInternal medicineCyclic GMP-Dependent Protein KinasesmedicineAnimalsHumansProtein IsoformsNADH NADPH OxidoreductasesLarge-Conductance Calcium-Activated Potassium ChannelsMice KnockoutNADPH oxidasebiologySuperoxideMicrofilament ProteinsNADPH OxidasesPhosphoproteinsMolecular biologyVasodilationEndocrinologymedicine.anatomical_structurechemistryGuanylate CyclaseNAD(P)H oxidaseNOX1ApocyninNADPH Oxidase 1biology.proteinEndothelium VascularCardiology and Cardiovascular MedicineSoluble guanylyl cyclaseCell Adhesion MoleculesSignal TransductionArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Combined sub-optimal doses of Rosuvastatin and Bexarotene impairs angiotensin II-induced arterial mononuclear cell adhesion through inhibition of Nox…

2015

Aim: Mononuclear cell (MC) infiltration into the arterial subendothelium is a key event in atherogenesis. Rosuvastatin (Rosu) and bexarotene (Bex) exert anti-inflammatory activity, but serious dose-related adverse effects have emerged. The need for safer and effective strategies to prevent and treat atherosclerosis led us to test the effect of combined use of both drugs on angiotensin II (Ang-II)-induced arterial MC recruitment. Results: Vehicle, Rosu (10–30 nM), Bex (0.3–1 μM), or a combination of both were administered to human umbilical arterial endothelial cells (HUAECs) 20 h before stimulation with 1 μM Ang-II (4 h). Surprisingly, a combination of Rosu (10 nM)+Bex (0.3 μM), which did n…

medicine.medical_specialtyTetrahydronaphthalenesPhysiologyPeroxisome Proliferator-Activated ReceptorsClinical BiochemistryCCL2BiologyNitric OxideBiochemistryPeripheral blood mononuclear cellCell LineInternal medicineCell AdhesionmedicineAnticarcinogenic AgentsHumansRosuvastatinInterleukin 8Rosuvastatin CalciumMolecular BiologyGeneral Environmental ScienceSistema cardiovascularBexaroteneSulfonamidesDiabetisArtèriesAngiotensin IIMembrane ProteinsNADPH OxidasesArteriesCell BiologyAngiotensin IIFluorobenzenesCXCL1Original Research CommunicationsPyrimidinesRetinoid X ReceptorsEndocrinologyNADPH Oxidase 5BexaroteneLeukocytes MononuclearGeneral Earth and Planetary SciencesSignal transductionSignal Transductionmedicine.drug
researchProduct

Diagnostic efficacy of the fluorometric determination of enzyme activity for Pompe disease from dried blood specimens compared with lymphocytes-possi…

2009

Pompe disease is a rare, autosomal-recessive disorder which results from a defect in the lysosomal enzyme acid alpha-glucosidase (GAA). The onset of this disease is highly variable, with infantile types being the most severe. Traditionally, lymphocytes, fibroblasts or muscle biopsies were necessary for enzyme activity measurement, because these materials do not express maltase-glucoamylase (MGA) that interferes with the assay. Recently, acarbose was found to inhibit MGA activity selectively, so that dried blood became accessible for GAA assessment.To evaluate the diagnostic efficacy of GAA measurement in dried blood specimens (DBSs) in comparison with lymphocytes. If DBSs provided reliable …

medicine.medical_specialtyTime FactorsLymphocyteBiopsyNeonatal ScreeningInternal medicineBiopsyGeneticsmedicineHumansFalse Positive ReactionsFluorometryLymphocytesGenetics (clinical)Acarbosechemistry.chemical_classificationNewborn screeningmedicine.diagnostic_testbiologybusiness.industryGlycogen Storage Disease Type IIMusclesInfant NewbornReproducibility of Resultsalpha-GlucosidasesEnzyme replacement therapyFibroblastsHydrogen-Ion ConcentrationEnzyme assaymedicine.anatomical_structureEndocrinologyEnzymechemistryCarbohydrate Metabolism Disorderbiology.proteinFeasibility Studiesbusinessmedicine.drugJournal of inherited metabolic disease
researchProduct

Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice

2012

Background & Aims CYLD is a tumor suppressor gene that is mutated in familial cylindromatosis, an autosomal dominant predisposition to tumors of skin appendages. Reduced CYLD expression has been observed in other tumor entities, including hepatocellular carcinoma. In the present study, we analyzed the role of CYLD in liver homeostasis and hepatocarcinogenesis in vivo . Methods Mice with liver-specific deletion of CYLDexon7/8 ( CYLD FF xAlbCre ) were generated. Liver tissues were histologically analyzed and oval cell activation was investigated. Hepatocarcinogenesis was induced by diethylnitrosamine/phenobarbital (DEN/PB). Microarray expression profiling of livers was performed in untreated …

medicine.medical_specialtyTumor suppressor geneBiliary Tract DiseasesIn Vitro TechniquesBiologymedicine.disease_causeDimethylnitrosamineDeubiquitinating Enzyme CYLDMiceRisk FactorsFibrosisInternal medicinemedicineAnimalsHomeostasisGenetic Predisposition to DiseaseHepatologyLiver NeoplasmsExonsTransforming growth factor betamedicine.diseaseFibrosisMice Mutant StrainsDeubiquitinating Enzyme CYLDMice Inbred C57BLGene expression profilingCysteine EndopeptidasesDisease Models AnimalPhenotypeEndocrinologyLiverPhenobarbitalHepatocellular carcinomaCancer researchbiology.proteinCell activationCarcinogenesisGene DeletionJournal of Hepatology
researchProduct

Is oxidative stress a therapeutic target in cardiovascular disease?

2010

An abnormal production of reactive oxygen species (ROS) and the subsequent decrease in vascular bioavailability of nitric oxide (NO) have long been proposed to be the common pathogenetic mechanism of the endothelial dysfunction, resulting from diverse cardiovascular risk factors such as hypercholesterolaemia, diabetes mellitus, chronic smoking, metabolic syndrome, and hypertension. Superoxide produced by the nicotinamide dinucleotide phosphate (NADPH) oxidase, mitochondrial sources, or the xanthine oxidase may react with NO, thereby resulting in excessive formation of peroxynitrite, a reactive nitrogen species that has been demonstrated to accelerate the atherosclerotic process by causing d…

medicine.medical_specialtyXanthine OxidaseAntioxidantmedicine.medical_treatmentmedicine.disease_causeArginineAntioxidantschemistry.chemical_compoundRisk FactorsInternal medicinemedicineHumansProspective StudiesEndothelial dysfunctionXanthine oxidaseReactive nitrogen specieschemistry.chemical_classificationReactive oxygen speciesNADPH oxidasebiologybusiness.industrySuperoxideNADPH OxidasesPolyphenolsVitaminsmedicine.diseasePrognosisMitochondriaOxidative StressEndocrinologychemistryCardiovascular Diseasesbiology.proteinEndothelium VascularNitric Oxide SynthaseCardiology and Cardiovascular MedicinebusinessReactive Oxygen SpeciesOxidative stressEuropean heart journal
researchProduct

Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease

2015

medicine.medical_specialtybusiness.industryLate onsetEnzyme replacement therapyDiseasemedicine.diseaseGastroenterologyNeurologyAlpha-GlucosidasesInternal medicineGlycogen storage disease type IImedicineJuvenileNeurology (clinical)businessAlglucosidase alfamedicine.drugJournal of the Neurological Sciences
researchProduct

Long-term cardiovascular risk of e-cigarettes

2020

medicine.medical_specialtybusiness.industryMEDLINEBrainNADPH OxidasesElectronic Nicotine Delivery SystemsTerm (time)Oxidative StressText miningCardiovascular DiseasesE-Cigarette VaporHeart Disease Risk FactorsRisk FactorsmedicineHumansCardiology and Cardiovascular MedicinebusinessIntensive care medicineEuropean Heart Journal
researchProduct

Protein kinase C-inhibiting properties of the losartan metabolite EXP3179 make the difference.

2009

The inhibition of the renin-angiotensin axis with the angiotensin II (ATII) receptor blockers, such as losartan, candesartan, and valsartan, has been demonstrated, similar to angiotensin-converting enzyme inhibitors, to reduce mortality in patients with arterial hypertension, chronic congestive heart failure, and acute myocardial infarction.1 Initially, the ATII receptor antagonist losartan helped to demonstrate new classes of ATII receptors and substantially expanded our knowledge about the cardiovascular effects of the renin-angiotensin-aldosterone system and its effector peptide ATII. Researchers dealing with this compound soon revealed that, beyond its antihypertensive effects attribute…

medicine.medical_specialtymedicine.drug_classMetabolitePharmacologyLosartanchemistry.chemical_compoundInternal medicineInternal MedicinemedicineHumansReceptorProtein Kinase CPhagocytesNADPH oxidasebiologyNADPH OxidasesReceptor antagonistAngiotensin IICandesartanEndocrinologyLosartanchemistryValsartanMatrix Metalloproteinase 9Hypertensionbiology.proteinAngiotensin II Type 1 Receptor Blockersmedicine.drugHypertension (Dallas, Tex. : 1979)
researchProduct